Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Single center retrospective evaluation of CHOP-based regimens in older patients with treatment naive blastic plasmacytoid dendritic cell neoplasm

View Full Paper
Ask AI
Bookmark
Share

Authors

CFCharles FoucarAPAnthony J. Perissinotti

Discussion

Loading...

Member takes

Overview

Retrospective analysis highlights induction chemotherapy response rates in older patients with BPDCN, suggesting a viable treatment option alongside allo-HCT.

Key Points

  • To evaluate the efficacy of CHOP-based regimens in older patients with treatment naive blastic plasmacytoid dendritic cell neoplasm (BPDCN).
  • Retrospective analysis of patients treated with CHOP-based induction regimens from January 1996 to February 2023.
  • Clinical outcomes assessed included complete remission rates and various response metrics after chemotherapy.
  • Utilized the University of Michigan EMERSE database for patient identification.
  • 92% of patients achieved a partial response after induction therapy.
  • 50% achieved complete remission or remission with incomplete count recovery.
  • The mean overall survival rate for all patients was 16.4 months, with higher rates in those receiving hematopoietic stem cell transplants.

Cite This Study

Foucar et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d31dhttps://doi.org/10.1182/blood-2025-6974
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Blastic plasmacytoid dendritic cell neoplasm (BPDCN) international registry: Assessment of the allo-HCT outcomes2025 · 1 citations
  2. 2Blastic plasmacytoid dendritic cell neoplasm: a Swiss case series of a very rare disease and a structured review of the literature2025
  3. 3Allogeneic hematopoietic cell transplantation as the standard of care for blastic plasmacytoid dendritic cell neoplasm in first complete remission.2025
  4. 4Real-world study of treatment landscape and safety outcomes of US patients with blastic plasmacytoid dendritic cell neoplasm2025 · 1 citations
  5. 5Frontline chemotherapy for CD30+ non-ALCL peripheral T-cell lymphoma a multi-center retrospective analysis2025